

Citations

1. Andy Crump, "Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations," *PubMed* 70(5) (2017): 495-505, doi: 10.1038/ja.2017.11.
2. Leon Caly et al. "The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 *in vitro*," *National Center for Biotechnology Information* (178) (2020): 104787, doi: 10.1016/j.antiviral.2020.104787.
3. Hemant Kumar Rout, "Ivermectin prophylaxis leads to 73 per cent reduction in Covid infection: AIIMS-Bhubaneswar study," last modified November 5, 2020, <https://www.newindianexpress.com/states/odisha/2020/nov/05/ivermectin-prophylaxis-leads-to-73-per-centreduction-in-COVID-infectionaiims-bhubaneswar-study-2219438.html>.
4. Zagazig University, "Prophylactic Ivermectin in COVID-19 Contacts," last modified August 27, 2020, ClinicalTrials.gov Identifier: NCT04422561.
5. Mohammed Tarek Alam et al. "A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline," (2020), *ResearchGate* doi: 10.3329/jbcps.v38i0.47512.
6. Mathieu Gendrot et al. "In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2," *National Center for Biotechnology Information* 25(21) (2020): doi: 10.3390/molecules25215064.

7. Juliana Cepelowicz Rajter, MD et al. “Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study,” *National Center for Biotechnology Information* 159(1) (2021): 85–92, doi: 10.1016/j.chest.2020.10.009.
8. Andrew Hill, MD, “Unitaid, Part of the World Health Organization Funding Ivermectin Research Targeting COVID-19 led by British Expert,” *TrialSite News* (blog), December 29, 2020, <https://trialsitenews.com/unitaid-part-of-the-world-health-organization-funding-ivermectin-research-targeting-COVID-19-led-by-british-expert/>.
9. Tratamiento Temprano, “Ivermectin meta-analysis by Dr. Andrew Hill,” December 27, 2020, video, 11:59, <https://www.youtube.com/watch?v=yOAh7GtvcOs>.
10. “COVID-19 Treatment Guidelines: What’s New,” *NIH* online, last modified January 14, 2021, <https://www.covid-19treatmentguidelines.nih.gov/whats-new/>.
11. “Dr. Pierre Kory, president of the FLCCC Alliance testifies before Senate Committee on Homeland Security and Governmental Affairs looking into early outpatient COVID-19 treatment,” *The FLCCC Alliance* online, December 8, 2020, <https://www.newswise.com/coronavirus/dr-pierre-kory-president-of-the-flccc-alliance-testifies-before-senate-committee-on-homeland-security-and-governmental-affairs-looking-into-early-outpatient-COVID-19-treatment>.
12. Markus Depfenhart et al. “Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy?,” *National Center for Biotechnology Information* (2020): 1–12, doi: 10.1007/s11739-020-02383-3.
13. Khalil Ansarin et al. “Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial,” *National Center for Biotechnology Information* 10(4) (2020): 209–215, doi: 10.34172/bi.2020.27.

14. Philippe Gautret et al. "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial," *National Center for Biotechnology Information* 56(1) (2020): 105949, doi: 10.1016/j.ijantimicag.2020.105949.
15. Aline Schögl et al. "Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells," *European Respiratory Journal* 45 (2015): 428-439, doi: 10.1183/09031936.00102014.
16. Mandeep R. Mehra, MD et al. "RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis," *The Lancet* (2020), doi: [https://doi.org/10.1016/S0140-6736\(20\)31180-6](https://doi.org/10.1016/S0140-6736(20)31180-6).
17. Catherine Offord, "The Surgisphere Scandal: What Went Wrong?," October 1, 2020, <https://www.the-scientist.com/features/the-surgisphere-scandal-what-went-wrong--67955>.
18. Joseph Magagnoli, M.S. et al. "Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19," *National Center for Biotechnology Information* preprint (2020), doi: 10.1101/2020.04.16.20065920.
19. "Response to Magagnoli," *MedRxiv*, PDF, 2020, <https://www.mediterranean-infection.com/wp-content/uploads/2020/04/Response-to-Magagnoli.pdf>.
20. N. Engl J. Med. "Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 (2020): NEJMoa2022926," *National Center for Biotechnology Information* doi: 10.1056/NEJMoa2022926; Mayla Gabriela Silva Borba, MD et al. "Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial," *JAMA Network* 3(4) (2020): e208857, doi:10.1001/jamanetworkopen.2020.8857.
21. *BMJ*, "Covid-19: The inside story of the RECOVERY trial," (2020): 370, doi: <https://doi.org/10.1136/bmj.m2670>.

22. Le Collectif Cityoen, "Oxford, Recovery et Solidarity: Overdosage in two clinical trials with acts considered criminal?," June 25, 2020, https://owl.purdue.edu/owl/research_and_citation/chicago_manual_17th_edition/cmos_formatting_and_style_guide/web_sources.html.
23. Caleb P. Skipper, MD et al. "Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19," *Annals of Internal Medicine* (2020), doi: <https://doi.org/10.7326/M20-4207>.
24. Clotilde Chatre et al. "Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature," *PubMed* 41(10) (2018): 919-931, doi: 10.1007/s40264-018-0689-4.
25. Sarah M. Lofgren et al. "Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19," *National Institutes of Health preprint* (2020), doi: 10.1101/2020.07.16.20155531.
26. Harvey A Risch "Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic Crisis," *American Journal of Epidemiology* 189 (11) (2020): 1218–1226, doi: <https://doi.org/10.1093/aje/kwaa093>.
27. Samia Arshad et al. "Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19," *International Society of Infectious Diseases* 97 (2020): 396-403, doi: <https://doi.org/10.1016/j.ijid.2020.06.099>.
28. Antonella d'Arminio Monforte et al. "Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal?," *National Center for Biotechnology Information* 99 (2020): 75-76, doi: 10.1016/j.ijid.2020.07.056.
29. Jean-Christophe Lagier et al. "Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis," *ScienceDirect* 36 (2020): 101791, doi: <https://doi.org/10.1016/j.tmaid.2020.101791>.

30. M. Million et al. "Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world," *National Center for Biotechnology Information* 38 (2020): 100709, doi: 10.1016/j.nmni.2020.100709.
31. Scott A. Read et al. "The Role of Zinc in Antiviral Immunity," *National Center for Biotechnology Information* 10(4) (2019): 696-710, doi: 10.1093/advances/nmz013.
32. E.J. Mundell "Could Zinc Help Fight COVID-19?," September 23, 2020, <https://www.webmd.com/lung/news/20200923/could-zinc-help-fight-covid-19>.
33. "Treatment with Zinc is Associated with Reduced In-Hospital Mortality Among COVID-19 Patients: A Multi-Center Cohort Study," *Research Square*, PDF, preprint, <https://assets.researchsquare.com/files/rs-94509/v1/0a05d31d-ce95-4559-a964-4280ab05ef9f.pdf>.
34. "Treatment of SARS-CoV-2 with high dose oral zinc salts: A report on four patients," *International Journal of Infectious Diseases*, PDF, 2020, [https://www.ijidonline.com/article/S1201-9712\(20\)30441-0/pdf](https://www.ijidonline.com/article/S1201-9712(20)30441-0/pdf).
35. Emily Shon, "Zinc may ward off viruses but there are dangers," December 21, 2009, <https://www.latimes.com/health/la-he-zinc21-2009dec21-story.html>.
36. Lili Chen et al. "Binding interaction of quercetin-3- β -galactoside and its synthetic derivatives with SARS-CoV 3CL^{pro}: Structure-activity relationship studies reveal salient pharmacophore features," *National Center for Biotechnology Information* 4(24) (2006): 8295-8306, doi: 10.1016/j.bmc.2006.09.014.
37. Ruben Manuel Luciano Colunga Biancatelli et al. "Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19)," *National Center for Biotechnology Information* 11 (2020): 1451, doi: 10.3389/fimmu.2020.01451.

38. Satish Sagar et al. "Bromelain Inhibits SARS-CoV-2 Infection in VeroE6 Cells," *PubMed* preprint (2020), doi: 10.1101/2020.09.16.297366.
39. Bengu Arslan et al. "Synergistic Effect of Quercetin and Vitamin C Against COVID-19: Is a Possible Guard for Front Liners," *SSRN* preprint (2020), doi: <http://dx.doi.org/10.2139/ssrn.3682517>.
40. Cesidio Giuliani et al. "The flavonoid quercetin inhibits thyroid-restricted genes expression and thyroid function," *National Center for Biotechnology Information* 66(23) (2014): 9, doi: 10.1016/j.fct.2014.01.016.
41. Maddie Sofia, "How Effective Are Antibody Treatments For COVID-19?," December 7, 2020, in *Short Wave*, produced by NPR, podcast, MP3 audio, 12:00, <https://www.npr.org/transcripts/942919330>.
42. "Convalescent plasma therapy," *Mayo Clinic* online, 21, 2021, <https://www.mayoclinic.org/tests-procedures/convalescent-plasma-therapy/about/pac-20486440#:~:text=Data%20from%20small%20clinical%20trials,effective%20treatment%20for%20COVID%2D19%20>.
43. Michael J. Joyner, MD et al. "Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19," *The New England Journal of Medicine* (2021), doi: 10.1056/NEJMoa2031893.
44. Brendan Borrell, "New York clinical trial quietly tests heartburn remedy against coronavirus," April 26, 2020, <https://www.sciencemag.org/news/2020/04/new-york-clinical-trial-quietly-tests-heartburn-remedy-against-coronavirus>.
45. Jeffrey F. Mather, MS et al. "Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19," *National Center for Biotechnology Information* published online 2020, doi: 10.14309/ajg.0000000000000832.
46. Samrat Yeramaneni et al. "Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System," *National*

Center for Biotechnology Information preprint (2020),
doi: 10.1053/j.gastro.2020.10.011.

47. Becky McCall, "Vitamin D Deficiency in COVID-19 Quadrupled Death Rate," December 11, 2020, <https://www.medscape.com/viewarticle/942497>.
48. Nikki Hancocks, "Experts send Vitamin D and Covid-19 open letter to world's governments," last modified December 21, 2020, <https://www.nutraingredients.com/Article/2020/12/21/Experts-send-Vitamin-D-and-Covid-19-open-letter-to-world-s-governments#>.
49. Ashu Rastogi et al. "Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study)," *BMJ Journal* doi: <http://dx.doi.org/10.1136/postgradmedj-2020-139065>.
50. Marta Entrenas Castillo et al. "Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study," *ScienceDirect* 203 (2020): 105751, doi: <https://doi.org/10.1016/j.jsbmb.2020.105751>.
51. Adeleh Sahebnaasagh et al. "The prophylaxis and treatment potential of supplements for COVID-19," *National Center for Biotechnology Information* 887 (2020): 173530, doi: 10.1016/j.ejphar.2020.173530.
52. Michael A. Matthay et al. "Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties," *The Lancet* 8(12) (2020): 1170-1172, doi: [https://www.thelancet.com/journals/lanres/article/PIIS2213-2600\(20\)30503-8/fulltext#%20](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30503-8/fulltext#%20).
53. Eugenio D. Hottz et al. "Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19," *Ash Publications* (2020), doi: <https://doi.org/10.1182/blood.2020007252>;
Bhanu Kanth Manne et al. "Platelet gene expression and function in patients with COVID-19," *Ash Publications* (2020), doi: <https://doi.org/10.1182/blood.2020007214>.

54. “Association of Mortality and Aspirin Prescription for COVID-19 Patients at the Veterans Health Administration,” *MedRxiv*, PDF, 2020,
<https://www.medrxiv.org/content/10.1101/2020.12.13.20248147v1.full.pdf>.
55. “Featured Review: Do blood thinners prevent people who are hospitalised with COVID-19 from developing blood clots?,” *Cochrane*, accessed January 22, 2021,
https://owl.purdue.edu/owl/research_and_citation/chicago_manual_17th_edition/cmos_formatting_and_style_guide/web_sources.html.

